代谢生物标志物特征用于区分胰腺导管腺癌与慢性胰腺炎
在三个三级转诊中心前瞻性招募914名受试者(胰腺导管腺癌271例、慢性胰腺炎282例、肝硬化100例、健康及非胰腺疾病对照261例),通过代谢组学筛选出由9种代谢物加CA19-9组成的生物标志物特征。该特征在训练集区分胰腺导管腺癌与慢性胰腺炎的AUC为0.96,在测试集AUC为0.94,成功验证。在慢性胰腺炎患者中,该特征的阴性预测值在训练集为99.9%,测试集为99.8%。
要点
- 由9种代谢物加CA19-9组成的生物标志物特征可区分胰腺导管腺癌与慢性胰腺炎。
- 训练集AUC 0.96,测试集AUC 0.94,成功验证了该特征。
- 在慢性胰腺炎患者中,阴性预测值训练集99.9%、测试集99.8%。
核心结论
- 在具有胰腺癌风险(累积发病率1.95%)的慢性胰腺炎患者中,该生物标志物特征的阴性预测值在训练集为99.9%(95%CI 99.7%-99.9%),在测试集为99.8%(95%CI 99.6%-99.9%)。
- 在三分之一患者中,与CA19-9相比,使用该生物标志物特征可改善诊断和治疗分层。
研究设计与样本
- 在三个三级转诊中心开展病例对照研究,连续三项研究前瞻性招募914名受试者,包括胰腺导管腺癌271例、慢性胰腺炎282例、肝硬化100例、健康及非胰腺疾病对照261例。
- 采用气相色谱-质谱联用和液相色谱-串联质谱联用鉴定477种代谢物,生成血浆和血清样本的代谢组学图谱。
主要发现
- 鉴定出由9种代谢物加CA19-9组成的生物标志物特征,用于胰腺导管腺癌与慢性胰腺炎的鉴别诊断。
- 训练集中该特征区分胰腺导管腺癌与慢性胰腺炎的AUC为0.96(95%CI 0.93-0.98)。
- 以0.384为截断值、固定特异度85%时,训练集敏感度为94.9%(95%CI 87.0%-97.0%)。
- 测试集AUC为0.94(95%CI 0.91-0.97),使用相同截断值时敏感度为89.9%(95%CI 81.0%-95.5%),特异度为91.3%(95%CI 82.8%-96.4%)。
关键数值与推荐
- 生物标志物特征截断值为0.384,固定特异度85%。
- 训练集敏感度94.9%(95%CI 87.0%-97.0%),AUC 0.96(95%CI 0.93-0.98)。
- 测试集敏感度89.9%(95%CI 81.0%-95.5%),特异度91.3%(95%CI 82.8%-96.4%),AUC 0.94(95%CI 0.91-0.97)。
- 慢性胰腺炎患者中阴性预测值训练集99.9%(95%CI 99.7%-99.9%),测试集99.8%(95%CI 99.6%-99.9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current non-invasive diagnostic tests can distinguish between pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC)) and chronic pancreatitis (CP) in only about two thirds of patients. We have searched for blood-derived metabolite biomarkers for this diagnostic purpose. DESIGN: For a case-control study in three tertiary referral centres, 914 subjects were prospectively recruited with PDAC (n=271), CP (n=282), liver cirrhosis (n=100) or healthy as well as non-pancreatic disease controls (n=261) in three consecutive studies. Metabolomic profiles of plasma and serum samples were generated from 477 metabolites identified by gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry. RESULTS: A biomarker signature (nine metabolites and additionally CA19-9) was identified for the differential diagnosis between PDAC and CP. The biomarker signature distinguished PDAC from CP in the training set with an area under the curve (AUC) of 0.96 (95% CI 0.93-0.98). The biomarker signature cut-off of 0.384 at 85% fixed specificity showed a sensitivity of 94.9% (95% CI 87.0%-97.0%). In the test set, an AUC of 0.94 (95% CI 0.91-0.97) and, using the same cut-off, a sensitivity of 89.9% (95% CI 81.0%-95.5%) and a specificity of 91.3% (95% CI 82.8%-96.4%) were achieved, successfully validating the biomarker signature. CONCLUSIONS: In patients with CP with an increased risk for pancreatic cancer (cumulative incidence 1.95%), the performance of this biomarker signature results in a negative predictive value of 99.9% (95% CI 99.7%-99.9%) (training set) and 99.8% (95% CI 99.6%-99.9%) (test set). In one third of our patients, the clinical use of this biomarker signature would have improved diagnosis and treatment stratification in comparison to CA19-9.
引用
- Mayerle J, Kalthoff H, Reszka R, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2017. PMID: 28108468. doi:10.1136/gutjnl-2016-312432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。